Literature DB >> 7845541

Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide.

J M Reul1, M S Labeur, D E Grigoriadis, E B De Souza, F Holsboer.   

Abstract

The effects of the reversible monoamine oxidaseA (MAOA) inhibitor moclobemide on the rat hypothalamic-pituitary-adrenocortical (HPA) axis were studied. The time-course experiments showed that moclobemide, given via the drinking water (4.5 mg/kg/day), produces significant decreases (p < 0.05) in adrenal weight after 5 (-23%) and 7 weeks (-16%) of treatment. It was found that long-term moclobemide treatment had neuroanatomically distinct effects on corticosteroid receptor expression. Hippocampal mineralocorticoid receptor (MR) levels were upregulated at 2 (+65%), 5 (+76%) and 7 (+19%) weeks of treatment. Glucocorticoid receptor (GR) levels in this limbic brain structure were slightly up-regulated by 10% at 5 weeks, and indistinguishable from controls after 2 and 7 weeks of treatment. After 5 weeks of treatment, MR levels were unchanged in the hypothalamus, and increased by 44, 24 and 28% in the neocortex, amygdala and anterior pituitary, respectively. GR concentrations were elevated by 24 and 14% in the hypothalamus and anterior pituitary, respectively, whereas neocortical and amygdaloid receptor levels were not altered. After 5 weeks of moclobemide treatment, marked decreases in [125I]Tyr0-ovine corticotropin-releasing hormone ([125I])-oCRH binding capacity and proopiomelanocortin (POMC) mRNA content were observed in the anterior pituitary. Regarding the functional implications of long-term anti-depressant treatment, moclobemide treatment (5 weeks, 4.5 mg/kg/day) significantly attenuated stress (30-min novel environment)-induced plasma ACTH (-35%) and corticosterone (-29%) levels; no changes were observed in basal plasma ACTH and corticosterone levels. In conclusion, this study shows that moclobemide has a concerted influence on multiple elements of the HPA axis manifesting functionally as a reduced neuroendocrine responsiveness to stress. In previous experiments, it was found that the structurally and pharmacologically distinct antidepressant amitriptyline after long-term administration also attenuated HPA axis activity. We postulate that an adjustement of HPA axis activity may be regarded as a common denominator for clinically efficacious antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7845541     DOI: 10.1159/000126788

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  23 in total

1.  Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Peter Zwanzger; Martina Jordan; Renate Buechs; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2006-04-22       Impact factor: 4.530

Review 2.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

Review 3.  Dissection of glucocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis by gene targeting in mice.

Authors:  Gloria Laryea; Lisa Muglia; Melinda Arnett; Louis J Muglia
Journal:  Front Neuroendocrinol       Date:  2014-09-27       Impact factor: 8.606

4.  Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone.

Authors:  Y Dwivedi; H S Rizavi; G N Pandey
Journal:  Neuroscience       Date:  2006-02-24       Impact factor: 3.590

5.  Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress.

Authors:  Aynara C Wulsin; James P Herman; Matia B Solomon
Journal:  Psychoneuroendocrinology       Date:  2010-02-10       Impact factor: 4.905

Review 6.  Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?

Authors:  L Cardamone; M R Salzberg; T J O'Brien; N C Jones
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

7.  Regulation of corticosteroid receptor gene expression in depression and antidepressant action.

Authors:  N Barden
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

Review 8.  Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression.

Authors:  Nicholas Barden
Journal:  J Psychiatry Neurosci       Date:  2004-05       Impact factor: 6.186

Review 9.  Repetitive transcranial magnetic stimulation : does it have potential in the treatment of depression?

Authors:  Frank Padberg; Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Sibylle Häfner; Christoph Born; Sascha Herrmann; Rainer Rupprecht
Journal:  PLoS One       Date:  2009-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.